Molecular Characterization of Ambiguous Mutations in HIV-1 Polymerase Gene: Implications for Monitoring HIV Infection Status and Drug Resistance

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Zheng, Du Ping ^a   Rodrigues, Margarida ^b   Bile, Ebi ^c   Nguyen, Duc B ^d   Diallo, Karidia ^a   DeVos, Joshua R ^a   Nkengasong, John N ^a   Yang, Chunfu ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CDC GAP Angola   (Angola)

^c CDC Botswana (BOTUSA)   (Botswana)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMINO ACID SUBSTITUTION; ANGOLA; ANTIVIRAL RESISTANCE; ARTICLE; BOTSWANA; CHINA; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KENYA; MAJOR CLINICAL STUDY; MALAWI; MUTATION RATE; NONHUMAN; NUCLEOTIDE SEQUENCE; STRUCTURAL GENE; TANZANIA; UNINDEXED SEQUENCE; VIET NAM;

DRUG RESISTANCE, VIRAL; GENES, POL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION;

EID: 84885803255     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077649     Document Type: Article

References (47)

1. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLOS ONE 4: e4724. doi:10.1371/journal.pone.0004724. PubMed: 19266092.
2. Wensing AM, Boucher CA, (2003) Worldwide transmission of drug-resistant HIV. AIDS Res 5: 140-155. PubMed: 14598563.
3. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, et al. (2008) Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLOS Med 5: e158. doi:10.1371/journal.pmed.0050158. PubMed: 18666824.
4. Sungkanuparph S, Oyomopito R, Sirivichayakul S, Sirisanthana T, Li PC, et al. (2011) HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clin Infect Dis 52: 1053-1057. doi:10.1093/cid/cir107. PubMed: 21460324.
5. WHO (2012). WHO HIV Drug Resistance Report 2012. World Health Organization.
6. Who U, UNICEF (2011) Global HIV/AIDS Response: Epidemic Update and Health Sector Progress Towards Universal Access. WHO Publication.
7. Oette M, Schülter E, Rosen-Zvi M, Peres Y, Zazzi M, et al. (2012) Efficacy of antiretroviral therapy switch in HIV-infected patients: a 10-year analysis of the EuResist Cohort. Intervirology 55: 160-166. doi:10.1159/000332018. PubMed: 22286887.
8. Ekstrand ML, Shet A, Chandy S, Singh G, Shamsundar R, et al. (2011) Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India. Int Health 3: 27-34. doi:10.1016/j.inhe.2010.11.003. PubMed: 21516199.
9. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. (2013) Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 21: 6-14. PubMed: 23596273.
10. Brookmeyer R, (2010) Measuring the HIV/AIDS epidemic: approaches and challenges. Epidemiol Rev 32: 26-37. doi:10.1093/epirev/mxq002. PubMed: 20203104.
11. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF, (2008) Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 13 (Suppl 2):: 25-36. PubMed: 18575189.
12. Myatt M, Bennett DE, (2008) A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antivir Ther 13 (Suppl 2):: 37-48. PubMed: 18575190.
13. Cohen MS, Gay CL, Busch MP, Hecht FM, (2010) The detection of acute HIV infection. J Infect Dis 202 (Suppl 2):: S270-S277. doi:10.1086/655651. PubMed: 20846033.
14. Guy R, Gold J, Calleja JM, Kim AA, Parekh B, et al. (2009) Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis 9: 747-759. doi:10.1016/S1473-3099(09)70300-7. PubMed: 19926035.
15. Parekh BS, McDougal JS, (2005) Application of laboratory methods for estimation of HIV-1 incidence. Indian J Med Res 121: 510-518. PubMed: 15817960.
16. Laeyendecker O, Brookmeyer R, Oliver AE, Mullis CE, Eaton KP, et al. (2011) Factors Associated with Incorrect Identification of Recent HIV Infection Using the BED Capture Immunoassay. AIDS Res Hum Retrovir, 28: 816-22. PubMed: 22014036.
17. Preston BD, Poiesz BJ, Loeb LA, (1988) Fidelity of HIV-1 reverse transcriptase. Science 242: 1168-1171. doi:10.1126/science.2460924. PubMed: 2460924.
18. Roberts JD, Bebenek K, Kunkel TA, (1988) The accuracy of reverse transcriptase from HIV-1. Science 242: 1171-1173. doi:10.1126/science.2460925. PubMed: 2460925.
19. Suzuki Y, Yamaguchi-Kabata Y, Gojobori T, (2000) Nucleotide substitution rates of HIV-1. AIDS Res 2: 39-47.
20. Rambaut A, Posada D, Crandall KA, Holmes EC, (2004) The causes and consequences of HIV evolution. Nat Rev Genet 5: 52-61. doi:10.1038/nrg1246. PubMed: 14708016.
21. Lemey P, Rambaut A, Pybus OG, (2006) HIV evolutionary dynamics within and among hosts. AIDS Res 8: 125-140. PubMed: 17078483.
22. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7557. doi:10.1073/pnas.0802203105. PubMed: 18490657.
23. Kouyos RD, von Wyl V, Yerly S, Böni J, Rieder P, et al. (2011) Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin Infect Dis 52: 532-539. doi:10.1093/cid/ciq164. PubMed: 21220770.
24. Ragonnet-Cronin M, Aris-Brosou S, Joanisse I, Merks H, Vallée D, et al. (2012) Genetic diversity as a marker for timing infection in HIV-infected patients: evaluation of a 6-month window and comparison with BED. J Infect Dis 206: 756-764. doi:10.1093/infdis/jis411. PubMed: 22826337.
25. Andersson E, Shao W, Bontell I, Cham F, Cuong DD, et al. (2013) Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. Infect Genet Evol 18C: 125-131. PubMed: 23583545.
26. Ugbena R, Aberle-Grasse J, Diallo K, Bassey O, Jelpe T, et al. (2012) Virological Response and HIV Drug Resistance 12 Months After Antiretroviral Therapy Initiation at 2 Clinics in Nigeria. Clin Infect Dis 54 (Suppl 4):: S375-S380. doi:10.1093/cid/cir1064. PubMed: 22544206.
27. Bussmann H, de la Hoz Gomez F, Roels TH, Wester CW, Bodika SM, et al. (2011) Prevalence of transmitted HIV drug resistance in Botswana: lessons learned from the HIVDR-Threshold Survey conducted among women presenting for routine antenatal care as part of the 2007 national sentinel survey. AIDS Res Hum Retrovir 27: 365-372. doi:10.1089/aid.2009.0299. PubMed: 21034246.
28. Duc NB, Hien BT, Wagar N, Tram TH, Giang le T, et al. (2012) Surveillance of Transmitted HIV Drug Resistance Using Matched Plasma and Dried Blood Spot Specimens From Voluntary Counseling and Testing Sites in Ho Chi Minh City. Vietnam: 2007-2008. Clin Infect Dis 54 (Suppl 4):: S343-347.
29. Kamoto K, Aberle-Grasse J, (2008) Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 13 (Suppl 2):: 83-87. PubMed: 18575195.
30. Nguyen HT, Duc NB, Shrivastava R, Tran TH, Nguyen TA, et al. (2008) HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam. Antivir Ther 13 (Suppl 2):: 115-121. PubMed: 18575200.
31. Somi GR, Kibuka T, Diallo K, Tuhuma T, Bennett DE, et al. (2008) Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther 13 (Suppl 2):: 77-82. PubMed: 18575194.
32. Zhang J, Kang D, Fu J, Sun X, Lin B, et al. (2010) Surveillance of transmitted HIV type 1 drug resistance in newly diagnosed hiv type 1-infected patients in Shandong Province, China. AIDS Res Hum Retrovir 26: 99-103. doi:10.1089/aid.2009.0184. PubMed: 20121622.
33. National AIDS/STDs Control Program FMoH, Abuja, Nigeria (2007) National Guideline for HIV and AIDS Treatment and Care in Adolescents and Adults.
34. Yang C, McNulty A, Diallo K, Zhang J, Titanji B, et al. (2010) Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J Clin Microbiol 48: 3158-3164. doi:10.1128/JCM.00564-10. PubMed: 20660209.
35. Zhou Z, Wagar N, DeVos JR, Rottinghaus E, Diallo K, et al. (2011) Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings. PLOS ONE 6: e28184. doi:10.1371/journal.pone.0028184. PubMed: 22132237.
36. Inzaule S, Yang C, Kasembeli A, Nafisa L, Okonji J, et al. (2013) Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. J Clin Microbiol 51: 529-539. doi:10.1128/JCM.02347-12. PubMed: 23224100.
37. Woods CK, Brumme CJ, Liu TF, Chui CK, Chu AL, et al. (2012) Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol 50: 1936-1942. doi:10.1128/JCM.06689-11. PubMed: 22403431.
38. Hall AG, (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41: 95-98.
39. Thanh DC, Hien NT, Tuan NA, Thang BD, Long NT, et al. (2009) HIV risk behaviours and determinants among people living with HIV/AIDS in Vietnam. AIDS Behav 13: 1151-1159. doi:10.1007/s10461-008-9451-8. PubMed: 18787940.
40. Kearney M, Palmer S, Maldarelli F, Shao W, Polis MA, et al. (2008) Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS 22: 497-501. doi:10.1097/QAD.0b013e3282f29478. PubMed: 18301062.
41. Lisovsky I, Schader SM, Martinez-Cajas JL, Oliveira M, Moisi D, et al. (2010) HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes. Antimicrob Agents Chemother 54: 2878-2885. doi:10.1128/AAC.01828-09. PubMed: 20404123.
42. Dean J, Ta Thi TH, Dunford L, Carr MJ, Nguyen LT, et al. (2011) Prevalence of HIV type 1 antiretroviral drug resistance mutations in Vietnam: a multicenter study. AIDS Res Hum Retrovir 27: 797-801. doi:10.1089/aid.2011.0013. PubMed: 21366425.
43. Cohen MS, Shaw GM, McMichael AJ, Haynes BF, (2011) Acute HIV-1 Infection. N Engl J Med 364: 1943-1954. doi:10.1056/NEJMra1011874. PubMed: 21591946.
44. Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, et al. (2010) Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 84: 6241-6247. doi:10.1128/JVI.00077-10. PubMed: 20375173.
45. Park SY, Love TM, Nelson J, Thurston SW, Perelson AS, et al. (2011) Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS 25: F13-F19. doi:10.1097/QAD.0b013e328349f089. PubMed: 21716075.
46. Kearney M, Maldarelli F, Shao W, Margolick JB, Daar ES, et al. (2009) Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol 83: 2715-2727. doi:10.1128/JVI.01960-08. PubMed: 19116249.
47. Gianella S, Richman DD, (2010) Minority variants of drug-resistant HIV. J Infect Dis 202: 657-666. doi:10.1086/655397. PubMed: 20649427.